Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Shah ED. Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2021;6:416-7. [PMID: 33765446 DOI: 10.1016/S2468-1253(21)00056-X] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Revised: 02/01/2021] [Accepted: 02/02/2021] [Indexed: 12/19/2022]

For:	Shah ED. Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2021;6:416-7. [PMID: 33765446 DOI: 10.1016/S2468-1253(21)00056-X] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Revised: 02/01/2021] [Accepted: 02/02/2021] [Indexed: 12/19/2022]

Number

Cited by Other Article(s)

Glissen Brown JR, Lembo AJ. Therapeutics, Placebo, and the Importance of Hard Outcomes in Irritable Bowel Syndrome Research. Clin Gastroenterol Hepatol 2022;20:e921-e922. [PMID: 34752965 DOI: 10.1016/j.cgh.2021.10.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Accepted: 10/28/2021] [Indexed: 02/07/2023]